CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Bristol Myers Squibb›
Products & Services›
Sotyktu (deucravacitinib)›
News
Sotyktu (deucravacitinib)

Bristol Myers Squibb› offers Sotyktu (deucravacitinib)

ProductOperating Status: Currently Offered

Sotyktu (deucravacitinib) is Bristol Myers Squibb oral allosteric TYK2 inhibitor for plaque psoriasis.

Loading
Overview
News

Latest News About Sotyktu (deucravacitinib)

Bristol Myers Squibb Presents Sotyktu deucravacitinib Two-Year Data in Adults with Psoriatic Arthritis

Bristol Myers Squibb

Bristol Myers Squibb Presents Sotyktu deucravacitinib Two-Year Data in Adults with Psoriatic Arthritis

New two-year POETYK PsA-2 results showed durable efficacy and consistent safety for the Sotyktu therapy in adults with psoriatic arthritis.

Sep 17, 2026

European Commission Approves Sotyktu deucravacitinib for Active Psoriatic Arthritis in Adults

Bristol Myers Squibb

European Commission Approves Sotyktu deucravacitinib for Active Psoriatic Arthritis in Adults

European regulators cleared Sotyktu for adults with active psoriatic arthritis, extending the product reach in Europe.

May 8, 2026

FDA Approves First TYK2 Inhibitor for Adults With Active Psoriatic Arthritis

AJMC

FDA Approves First TYK2 Inhibitor for Adults With Active Psoriatic Arthritis

Phase 3 trials show deucravacitinib, the first TYK2 inhibitor approved for adults with active psoriatic arthritis, improves both joint and...

Mar 9, 2026

U.S. FDA Approves Sotyktu deucravacitinib for Adults with Active Psoriatic Arthritis

Bristol Myers Squibb

U.S. FDA Approves Sotyktu deucravacitinib for Adults with Active Psoriatic Arthritis

FDA approved Sotyktu for adults with active psoriatic arthritis, the first TYK2 inhibitor cleared for this indication.

Mar 6, 2026

U.S. Food and Drug Administration Approves Sotyktu deucravacitinib, Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis

Bristol Myers Squibb

U.S. Food and Drug Administration Approves Sotyktu deucravacitinib, Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis

FDA approved Sotyktu, a first-in-class oral selective TYK2 inhibitor, for adults with moderate-to-severe plaque psoriasis.

Sep 9, 2022